Jump to start of content

Complete requirements by 12/31/19 to avoid a change in certification status Expand/Collapse the ABIM alert.

Sign in to your Physician Portal to view any remaining requirements for the year. Not completing these requirements by 12/31/19 could result in a change to your certification status.

ABIM Scheduled Maintenance... Expand/Collapse the ABIM alert.

ABIM.org will be going through scheduled maintenance from 6 p.m. ET, Sat., 12/14 to 6 a.m. ET, Sun., 12/15. During this time, the ABIM Physician Portal will be unavailable.
We apologize for any inconvenience this may cause. Thank you for your patience.

Breadcrumb trail:

Hematology Board

Expand All | Collapse All

Mark M. Udden, MD, Chair

Mark M. Udden, MD Dr. Udden, a board certified hematologist and internist, is Chief of Benign Hematology and Professor of Medicine at Baylor College of Medicine (BCM) in Houston, Texas. He is Chief of Hematology at the Ben Taub General Hospital and Harris Health Smith Clinic. He is also an Attending Physician in the Baylor Clinic and consults at Baylor Saint Luke's Medical Center and the Texas Children's Hospital Pavilion for Women. He has a special interest in sickle cell disease and hematology of pregnancy. He also co-chairs the second-year medical student course in hematology/oncology and has an active teaching role for resident and fellowship training at Baylor.

He has served at Baylor as Core Clerkship Director for Internal Medicine from 1990 to 2007 and Chairman of the Longitudinal Ambulatory Care Experience course from 1994 to 1999. He was an adjunct Assistant then Associate Professor in the Biomedical Engineering Department at Rice University from 1983 until 1992.

Dr. Udden is Chair of the American Board of Internal Medicine (ABIM) Hematology Board. He is a fellow of the American College of Physicians. At Baylor, he has received numerous teaching awards including the Barbara and Corbin J. Robertson, Jr. Presidential Award for Excellence in Education in 2008 and the Master Clinician Lifetime Award in 2013.

He received his undergraduate degree from the Massachusetts Institute of Technology and his medical degree from The University of Texas Southwestern Medical School. He completed his residency in internal medicine and a fellowship in hematology at Baylor College of Medicine.

As of March 2019, Dr. Udden reported no external relationships.

Paul T. Adams, MD

Dr. Adams is a graduate of the Wayne State University School of Medicine. Internal Medicine Residency performed at Henry Ford Hospital in Detroit, MI followed by Hematology/Oncology Fellowship at the University of Michigan. A Faculty Member at the University of Michigan for 9 years, Dr. Adams serves as a member of American Board of Internal Medicine Hematology Board.

Presently, he is in private practice in Genesee Hem/Onc. Hem/Onc Fellowship Director at Genesys Regional Medical Center. Director of Hem/Onc Services at Genesys Regional Medical Center. Medical Director of Medical Oncology for Ascension Michigan.

As of December 2018, Dr. Adams reported the following external relationships:

Dr. Adams serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Ascension Health Michigan, Medical Director of Medical Oncology, Member of System Leadership Team, receiving salary support for a yearly contract.

Diane S. Blum, MS

Diane S. Blum, MSMs. Blum is a health care consultant with expertise in psychosocial care of the cancer patient, oncology research and education, and non-profit management.

Through 2013, she served as Chief Executive Officer of the Lymphoma Research Foundation, the nation's largest non-profit organization devoted to funding lymphoma research and providing education about the disease. Previously, for 20 years, Ms. Blum was Executive Director of CancerCare, a national non-profit support organization for people with all cancers. Before serving as executive director, she had been Director of Social Service at CancerCare and a Social Work Supervisor at Memorial Sloan Kettering Cancer Center and the Dana-Farber Cancer Institute.

Ms. Blum is a founder of National Breast Cancer Awareness Month, and for 12 years, served as Editor-in-Chief of Cancer.net, the American Society of Clinical Oncology (ASCO) website for patients and the public. She is a member of the American Board of Internal Medicine Hematology Board. She has served on committees of the Institutes of Medicine, ASCO and National Cancer Institute, and is on editorial boards of five oncology publications. Ms. Blum's awards include the Lifetime Achievement Award from the Board of Sponsors of National Breast Cancer Awareness Month, the Special Recognition Award from the National Coalition for Cancer Survivorship, the Republic Bank Breast Cancer Research Award, the ASCO Special Recognition Award and the 2009 ASCO Partners in Progress Award. This award recognized Ms. Blum's leadership in helping patients overcome the financial, educational, and emotional burdens that accompany a cancer diagnosis.

Ms. Blum received a bachelor's degree from the University of Rochester and a master's degree from the School of Social Welfare at the University of Buffalo.

As of April 2019, Ms. Blum reported the following external relationships:

Service on data and safety monitoring boards for the following companies, with compensation for travel expenses and honoraria:

  • Merck
  • Daiichi
  • Bayer
  • Pfizer

Beth M. Faiman, PhD, RN, MSN, ANP-BC, AOCN

Beth M. Faiman, PhD, RN, MSN, ANP-BC, AOCN

Dr. Beth Faiman received a bachelor of science in nursing and registered nurse certification at Ursuline College in Pepper Pike, Ohio, completed in 1996. She received a master of science in nursing and certification as an adult nurse practitioner at Kent State University in Kent, Ohio in 2002 and a PhD from Case Western Reserve University in 2014. Dr. Faiman holds an advanced oncology nurse certification through ONCC. She is employed as a Nurse Practitioner in the department of Hematology and Oncology at the Cleveland Clinic in Cleveland, Ohio.

She received the 2012 Excellence in Medical Oncology and 2013 Commendation for Patient and Nursing Education Awards sponsored by The Oncology Nursing Society; the 2015 Dean's Legacy Award for PhD Studies from Case Western, and was named the Leukemia and Lymphoma Society's Woman of the Year for Cleveland and Akron Ohio, 2016. She is an appointed delegate on the International Myeloma Foundation Nurse Leadership Board, Editor-in-Chief of The Oncology Nurse APN/PA and on the editorial board of ASH Clinical News. She serves as a member of the American Board of Internal Medicine Hematology Board. Dr. Faiman is an active author and educator on the topics of plasma cell dyscrasias, hematology and symptom manangement.

She led the development of myeloma nurse management guidelines, and influenced cancer care practice by presenting at 18 international and 210 US national/regional conferences. She served as lecture chair of 3 international and 63 national conferences. She has edited several books, authored many chapters, and written numerous articles relating to the diagnosis and treatment of blood cancers, treatment adherence, and cancer symptom management and remains active in clinical trials research.

As of December 2018, Dr. Faiman reported the following external relationships:

Funding for clinical trial expenses, paid to the Cleveland Clinic Foundation, from the following companies:

  • Celgene, for consulting and clinical trial expenses.
  • Janssen, for a trial of dartumumab.
  • Amgen, for a trial of carfilzomib and denosumab.
  • Bristol-Myers Squibb, for a trial of elotuzumab.

Service on data and safety monitoring boards for the following companies, with compensation for travel expenses:

  • Janssen, for clinical research in randomized trials for cancer.

Work as an author or editor for following companies, with compensation as listed:

  • American Society of Hematology, receiving compensation as Associate Editor of Advanced Practice.

Scott D. Gitlin, MD

Scott D. Gitlin, MDDr. Gitlin, a board certified internist and hematologist, is a Professor of Internal Medicine in the Division of Hematology/Oncology at the University of Michigan Medical Center and at the Veterans Affairs Ann Arbor Healthcare System. His academic activities and interests include laboratory and clinical/translational research projects, the care of patients with malignant and non-malignant hematology disorders and education and training of physicians and junior faculty.

Currently, Dr. Gitlin serves as a member of the American Board of Internal Medicine Hematology Board, a member of the Association of American Medical Colleges (AAMC) Board of Directors and is an Administrative Board member of the AAMC's Council of Faculty and Academic Societies. He is past member of the Board of Directors of the Alliance for Academic Internal Medicine (AAIM) and past President of the Association of Specialty Professors (ASP). He has served as Chair of the Hematology In-training Examination Test Writing Subcommittee of the American Society of Hematology. He is the 2014 recipient of the ASP/AAIM Eric G. Neilson, MD, Distinguished Professor Award. Dr. Gitlin has also had lead roles with the American Society of Hematology in the development of national and international mentoring, education and training programs for fellows and junior faculty who are interested in pursuing academic research careers.

Dr. Gitlin earned his medical degree at the University of Michigan Medical School. He did his residency in the Department of Internal Medicine at the University of Michigan and later completed his hematology/oncology fellowship training at the University of Michigan and the National Cancer Institute of the National Institutes of Health.

As of May 2019, Dr. Gitlin reported the following external relationships:

Dr. Gitlin received funding from Alexion to support expenses associated with enrollment of patients and reporting of clinical data for a clinical registry.

Dr. Gitlin also serves on an advisory board for Cardinal Health, with compensation for travel expenses and honoraria.

Dr. Gitlin serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Association of American Medical Colleges, Chair of the Council of Faculty and Academic Societies and member of the Board of Directors, receiving reimbursement for travel expenses.

Dr. Gitlin also receives compensation from the American Society of Hematology for attendance as a faculty member at Medical Educators' Institute.

Marc J. Kahn, MD, MBA

Marc J. Kahn, MD, MBADr. Kahn is the Peterman-Prosser Professor and Senior. Associate Dean at Tulane University School of Medicine where he has appointments in the Departments of Internal Medicine and Pharmacology in addition to the Tulane AB Freeman School of Business. Dr. Kahn’s research interests include medical education, non-malignant hematology and healthcare finance. He is board certified in Internal Medicine, Medical Oncology and Hematology.

Dr. Kahn is a member of the American Board of Internal Medicine Hematology Board. He served on the Board of Directors for the National Residency Matching Program. He also serves several leadership roles with the American College of Physicians (ACP) including serving as Chair of the Scientific Program Committee for 2018 and 2020 and as a contributor or editor for MKSAP 13 through 18. Dr. Kahn was elected a Master of the ACP in 2018. Additionally, he has served as National Chair of the Association of American Medical Colleges Group on Student Affairs. He has also held leadership positions with the American Society of Hematology (ASH), including serving as contributor or editor of the ASH SAP for the first five editions. He has also served as Vice Chair of the ASH Committee on Educational Affairs and served as the Inaugural Sr. Director of the ASH Medical Educator’s Institute. Dr. Kahn was elected a Fellow of the Royal College of Physicians, London.

Dr. Kahn received his bachelor and medical degrees from the University of Pennsylvania where he completed his internal medicine residency, chief medical residency and hematology/medical oncology fellowship. Dr. Kahn completed his master’s degree in business administration at Tulane’s AB Freeman School of Business in 2010.

As of February 2019, Dr. Kahn reported the following external relationships:

Dr. Kahn serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • National Residency Matching Program, Board Member, Chair of Violations Review Committee, Executive Committee Member, receiving reimbursement for travel expenses.
  • American College of Physician, Chair of Scientific Program Committee, Member of Chapter Education Committee, travel, receiving reimbursement for travel expenses.
  • American Society of Hematology, Vice Chair of Committee on Educational Affairs, Senior Director of American Society of Hematology Medical Educators Institute, Chair of Highlights of American Society of Hematology Committee, Member of Communications Committee, receiving reimbursement for travel expenses.

Selina M. Luger, MD

Selina M. Luger, MDDr. Selina Luger is a Professor of Medicine at the University of Pennsylvania where she is a member of the Hematologic Malignancies Program of the Abramson Cancer Center at the Hospital of the University of Pennsylvania. She received her undergraduate degree at Harvard, and her MD at McGill. She is a member of the Royal College of Physicians and Surgeons in Canada where she is board certified in Internal Medicine ( RCPSC) and she has active board certification in Hematology ( ABIM) and inactive but eligible for certification in Internal Medicine and Oncology (ABIM) . She serves as a member of the American Board of Internal Medicine Hematology Board.

She is actively involved with the American Society of Hematology where she is a member of the Committees on Scientific Affairs and she is Co-chair of the Women in Hematology Working Group. She is an Associate Editor of Blood. She is actively involved in clinical research in the Acute Leukemias and related myeloid disorders and serves as the co-chair of the Leukemia Committee and the AYA Subcommittee of the Eastern Cooperative Oncology Group.

As of June 2019, Dr. Luger reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Pennsylvania, from the following companies:

  • Oconova Therapeutics
  • Seattle Genetics
  • Roche
  • Biosight

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:

  • Jazz, for serving on an advisory board, receiving reimbursement for travel expenses and honoraria.
  • Pfizer, for serving on an advisory board, receiving honoraria.

Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:

  • Acute Leukemia Forum, speaking at a continuing medical education lecture.

Work as an author or editor for the following companies, with compensation as listed:

  • American Society of Hematology, receiving compensation as associate editor for Blood.

Dr. Luger serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Hematology, committee member and working group co-chair, receiving reimbursement for travel expenses.
  • Eastern Cooperative Oncology Group, committee co-chair, without compensation.

Marc S. Zumberg, MD

Dr. Zumberg is Professor and Section Chief Non-Malignant Hematology at the University of Florida College of Medicine, Gainesville, Florida. He is board certified in Hematology.

Dr. Zumberg has been a faculty member at the University of Florida since completing his combined fellowship in Hematology and Medical Oncology in 2000. He currently serves as Professor of Medicine and as Section Chief of Non-Malignant Hematology. From 2006-2014, he served as Associate Professor of Medicine and from 2000-2006, as Assistant Professor of Medicine. Dr. Zumberg has served as Medical Director for Therapeutic Apheresis for LifeSouth Community Blood Centers since 2000.

Dr. Zumberg served on the American Society of Hematology (ASH) committee on training programs from 2008-2015. He served as the ASH liaison on Maintenance of Certification to the American Board of Internal Medicine (ABIM) Hematology Board from 2015-2017, and currently serves as a member of the ABIM Hematology Board. He was an inaugural faculty member at the ASH Medical Educators Institute (MEI) where he subsequently served as faculty. He was recognized as the basic science teacher of the year at the University of Florida Medical School in 2017 and the hematology course he directs was voted best basic science course by the graduating medical students in 2016-2018.

Dr. Zumberg received a bachelor's degree in neurobiology in 1990 and his medical degree in 1994, both from the University of Michigan. He completed an internal medicine residency in 1997 and a hematology-oncology fellowship in 2000, both at the University of Florida.

As of July 2019, Dr. Zumberg reported the following external relationships.

Dr. Zumberg serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Society of Hematology, Highlights of American Society of Hematology lecturer, member of several committees, receiving consulting fees and reimbursement for travel expenses.
  • Best Doctors, receiving honoraria.

Dr. Zumberg is also a medical director for NCF Diagnostics.